What trials found Peptide care
A trial result needs its surrounding story.
These studies in people are called clinical trials. Their results are more useful when you know who took part, what treatments were compared and how long the study lasted.
The medicine studied here is tirzepatide (Mounjaro, Zepbound), used in diabetes and weight care.
Keep the comparison beside the claim
Who was studied matters
The SURMOUNT-1 group had either obesity or overweight with a weight-linked health problem; people with diabetes were excluded.
The SURMOUNT-1 trial compared groups taking different strengths of tirzepatide. After 72 weeks, those groups had lost an average of 15.0% to 20.9% of their starting weight, depending on the strength.
The dummy-shot group lost about 3% on average.
A dummy shot, also called a placebo, is used for comparison rather than delivering the study medicine.
The manufacturer supported the trial, which included check-ins and lifestyle counselling.
The end of treatment is another question
In SURMOUNT-4, everyone first took tirzepatide for 36 weeks. Some people then switched to dummy shots, which contained no tirzepatide. By week 88, the people who switched had gained an average of 14% compared with their weight at week 36, when they switched.
The people who kept taking tirzepatide lost an average of another 5.5% of their week-36 weight by week 88.
The comparison ran from week 36 to week 88.
That describes the trial, rather than deciding how long any particular person needs treatment.
Bring the result back to your own goal
Ask which part of the study resembles your situation and which part does not. Ask what the clinician would monitor besides weight.
Put the unwanted effects beside the evidence